Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.

@article{Kelly2010UtilityOO,
  title={Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.},
  author={Catherine M A Kelly and Savitri Krishnamurthy and G. L. Bianchini and Jennifer K Litton and Ana Mar{\'i}a Gonz{\'a}lez-Angulo and Gabriel N Hortobagyi and Lajos Pusztai},
  journal={Cancer},
  year={2010},
  volume={116 22},
  pages={5161-7}
}
BACKGROUND Oncotype DX breast cancer assay (Genomic Health, Redwood City, Calif) stratifies patients with early breast cancer according to risk of distant recurrence. The authors hypothesized that the test is ordered when clinicopathological variables yield equivocal risk estimates. The current study also showed how often the test clarifies clinically ambiguous risk status. METHODS The authors examined clinical/pathological characteristics and calculated risk of recurrence with Adjuvant! for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

patients : a population - based study

  • M Dowsett, J Cuzick, C Wales
  • 2008

Similar Papers

Loading similar papers…